Search company, investor...

Predict your next investment

Corporation
onxeo.com

Partners & Customers

10

About Onxeo

Onxeo (Paris: ONXEO) is a developer of orphan oncology drugs. The company is focused on developing therapeutics for rare cancers, one of the fastest growing markets in the healthcare industry with high, unmet medical needs. Onxeo's comprehensive portfolio features a broad orphan oncology pipeline, with three independent programs in advanced clinical development, including Onxeo's first approved orphan oncology drug, Beleodaq.

Headquarters Location

49 boulevard du General Martial Valin

Paris, 75015,

France

+33 (0)1 45 58 76 00

Want to inform investors similar to Onxeo about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Onxeo News

Onxeo to study prostate cancer drug

Jan 27, 2023

Photo/Shutterstock French biotech company Onxeo S.A. has given an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first U.S. clinical study site, Next Oncology San Antonio. This phase 1b/2 multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients with recurrent ovarian, breast and metastatic castration-resistant prostate cancer (mCRPC) who have progressed on previous PARP inhibitor therapy. The primary endpoint of the study will assess the safety and tolerability of the combination as well as to determine the recommended phase 2 dose. Key secondary endpoints will assess the preliminary activity and duration of response for the combination. ‘Important next step’ Shefali Agarwal, chairwoman of the board of directors and CEO, said: “We are delighted with the initiation of this important clinical trial in the U.S. to further explore the potential of our first-in-class drug candidate, AsiDNA. This investigational product has been in clinical development in Europe for the last few years, in recurrent solid tumors. In clinical studies AsiDNA appears to be well tolerated with encouraging clinical activity in the studied patients till date. The activation of this first study in the U.S. is an important next step towards its global clinical development. “The recent encouraging activity observed from the preliminary data in the REVOCAN study indicates the potential of AsiDNA to re sensitize patients to PARP therapy which potentially addresses an unmet need and could meaningfully impact patients living with recurrent ovarian cancer who have progressed on an initial treatment with a PARP inhibitor. “Additionally, this lays a strong foundation for our next first in class drug candidate OX425 which is sourced from the same proprietary PlatON platform and is a PARP/DDR specific decoy agonist thereby possibly not inducing tumor resistance to treatment. This profile represents a potential differentiation in safety and activity from other targeted therapies such as PARP inhibitors and we are on track to file an IND in mid- 2023.” Content continues below

Onxeo Acquisitions

3 Acquisitions

Onxeo acquired 3 companies. Their latest acquisition was DNA Therapeutics on February 29, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/29/2016

Seed / Angel

$99M

$1.1M

Acquired

2

5/22/2014

Series C

Subscribe to see more

$99M

$99M

Subscribe to see more

10

5/22/2014

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/29/2016

5/22/2014

5/22/2014

Investment Stage

Seed / Angel

Series C

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$1.1M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

2

10

10

Onxeo Partners & Customers

10 Partners and customers

Onxeo has 10 strategic partners and customers. Onxeo recently partnered with Institut Curie on September 9, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

9/1/2022

Partner

France

High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie

Shefali Agarwal , Onxeo S.A. 's President and Chief Executive Officer , stated : `` Onxeo S.A. is proud of its clinical collaboration with Institut Curie , and would like to thank Professor François Doz -- the study 's lead investigator -- for his involvement in this project .

2

2/4/2021

Partner

France

1

4/16/2020

Licensee

United States

Onxeo S.A.’s $6.6 Million Agreement with Acrotech Biopharma LLC

Onxeo S.A. , a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response , in particular against rare or resistant cancers , announced that it has entered into agreements with Acrotech , a wholly-owned subsidiary of Aurobindo Pharma , which extend Acrotech 's rights to belinostat , to all territories not previously covered under Onxeo S.A. 's prior agreement with Acrotech as well as transfer certain IP and know-how related to belinostat in all its forms .

1

1/29/2020

Partner

France

Subscribe to see more

Subscribe to see more

10

4/24/2017

Licensee

United States

Subscribe to see more

Subscribe to see more

10

Date

9/1/2022

2/4/2021

4/16/2020

1/29/2020

4/24/2017

Type

Partner

Partner

Licensee

Partner

Licensee

Business Partner

Country

France

France

United States

France

United States

News Snippet

High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie

Shefali Agarwal , Onxeo S.A. 's President and Chief Executive Officer , stated : `` Onxeo S.A. is proud of its clinical collaboration with Institut Curie , and would like to thank Professor François Doz -- the study 's lead investigator -- for his involvement in this project .

Onxeo S.A.’s $6.6 Million Agreement with Acrotech Biopharma LLC

Onxeo S.A. , a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response , in particular against rare or resistant cancers , announced that it has entered into agreements with Acrotech , a wholly-owned subsidiary of Aurobindo Pharma , which extend Acrotech 's rights to belinostat , to all territories not previously covered under Onxeo S.A. 's prior agreement with Acrotech as well as transfer certain IP and know-how related to belinostat in all its forms .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Onxeo Team

2 Team Members

Onxeo has 2 team members, including , .

Name

Work History

Title

Status

Gilles Avenard

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Gilles Avenard

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.